Terminology for sample collection in clinical genetic studies the Pharmacogenetics Working Group

Pharmacogenomics Journal

Volumn 1, Issue 2, 2001, Pages 101-103

  Spear, B B ^a   Heath Chiozzi, M E ^a   Barnes, D M ^a   Cheeseman, K ^b   Shaw, P ^c   Campbell, D A ^d   McCarthy, A ^d   Ray, S C ^e   Culver, K ^f   McHale, D ^g   Anderson, D C ^h   Dahlstroem, C ⁱ   Hashimoto, L ⁱ   Sandbrink, R ^j  

^a ABBOTT LABORATORIES   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

^f Novartis Pharmaceuticals Corporation   (Germany)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h PFIZER INC   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j BAYER PHARMA AG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; CLINICAL TRIAL; GENETICS; HUMAN; LABORATORY DIAGNOSIS; METHODOLOGY; NOMENCLATURE; PHARMACOGENETICS;

CLINICAL TRIALS; DNA; HUMANS; PHARMACOGENETICS; SPECIMEN HANDLING; TERMINOLOGY;

EID: 28644448646     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500037     Document Type: Article

References (5)

1. National Bioethics Advisory Commission (USA). Research Involving Human Biological Materials: Ethical Issues and Policy Guidance, 1999.
2. Medical Research Council (UK). Human Tissue and Biological Samples for Use in Research (for Consultation), 1999.
3. Council for International Organizations for Medical Sciences. Ethics and Epidemiology: International Cuidelines, 1990.
4. Human Genome Organization Ethics Committee. Statement on DNA Sampling: Control and Access, 1998.
5. World Health Organization. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services, 1997.